TAK
TAKEDA Terminates Phase 3 Soticlestat Study in Dravet and Lennox-Gastaut
Takeda has halted a Phase 3 trial of soticlestat in epilepsy patients previously exposed to fenfluramine, citing a business decision unrelated to patient safety.
TAK
Market-moving news on Takeda (TAK): filings, earnings, deals and other events, from REDFILED.